Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Condition(s) targeted: Non-Hodgkin's Lymphoma

Intervention: Iodine I 131 Tositumomab Therapeutic Regimen (Drug)

Status: No longer available

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, MD, Study Director, Affiliation: GlaxoSmithKline

This is a single arm, multi-center, expanded access study of Iodine I 131 Tositumomab (BEXXAR) therapeutic regimen for patients with relapsed or refractory low-grade or transformed low-grade non-Hodgkin's B-cell lymphoma. The primary objective is to make Iodine I 131 Tositumomab more broadly available to patients. Secondary endpoints will be to obtain additional safety and efficacy information for this treatment regimen. Post study drug administration follow-ups will continue for up to ten years. These will include blood-work and adverse event assessments for 13 weeks post dosing, patient response evaluations at Week 13, Months 6, 12, 18, 24, and Long-Term Follow-ups every 6 months until the elapse of 5 years from the dosimetric dose and then annually thereafter through year 10. Thyroid function will be monitored annually during Long-term follow-up.

Official title: Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma

Study design: Expanded Access

Minimum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Histologically confirmed diagnosis of low- grade NHL or transformed low-grade NHL (tumor must be CD 20 positive).

- Prior treatment with at least one chemotherapy regimen and have relapsed or progressed, or failed to achieve an objective response on last chemotherapy regimen.

- Karnofsky performance status of at least 60% and anticipated survival of at least 3 months.

- Absolute granulocyte of >/= 1,500/mm3.

- Platelet count of >/= 100,000/mm3, and not require sustained support of hematopoietic cytokines, or transfusion of blood products.

- Adequate renal function (i. e., <1. 5x Upper Limit of Normal), and hepatic transaminases (AST <5 times ULN).

- Signed IRB/IEC-approved informed consent.

Exclusion Criteria:

- Patients with a mean of >25% of the intratrabecular marrow space involved with lymphoma.

- Patients who received cytotoxic chemotherapy, radiation therapy, immunotherapy, or cytokine treatment within 4 weeks prior to study entry (6 weeks for nitrosurea compounds) or who exhibit persistent clinical evidence of toxicity.

- Patients who have undergone stem cell or bone marrow transplant, active obstructive hydronephrosis, active infection, New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation.

- Known HIV infection.

- Pregnant or nursing patients.

- Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, in-situ cervical cancer, or cancer for which the patient has been disease-free for 5 years.

- Patients with progressive disease within 1 year of irradiation arising in a field that has been previously irradiated with more than 3500 cGy.

- Patients who received prior radioimmunotherapy, known brain or leptomeningeal metastases, HAMA positivity.

- Patients who are receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics.

GSK Clinical Trials Call Center, Huntsville, Alabama 35801, United States

GSK Clinical Trials Call Center, Birmingham, Alabama 35205, United States

GSK Clinical Trials Call Center, Anchorage, Alaska 99508, United States

GSK Clinical Trials Call Center, Phoenix, Arizona 85013, United States

GSK Clinical Trials Call Center, Little Rock, Arkansas 72205, United States

GSK Clinical Trials Call Center, Newport Beach, California 92663, United States

GSK Clinical Trials Call Center, Vallejo, California 94589, United States

GSK Clinical Trials Call Center, San Francisco, California 94143, United States

GSK Clinical Trials Call Center, Stanford, California 94305, United States

GSK Clinical Trials Call Center, Washington, District of Columbia 20010, United States

GSK Clinical Trials Call Center, Miami, Florida 33136, United States

GSK Clinical Trials Call Center, Bay Pines, Florida 33708, United States

GSK Clinical Trials Call Center, Miami Beach, Florida 33140, United States

GSK Clinical Trials Call Center, Atlanta, Georgia 30342, United States

GSK Clinical Trials Call Center, Macon, Georgia 31201, United States

GSK Clinical Trials Call Center, Atlanta, Georgia 30309, United States

GSK Clinical Trials Call Center, Roswell, Georgia 30076, United States

GSK Clinical Trials Call Center, Chicago, Illinois 60612, United States

GSK Clinical Trials Call Center, Urbana, Illinois 61801, United States

GSK Clinical Trials Call Center, Maywood, Illinois 60153, United States

GSK Clinical Trials Call Center, Chicago, Illinois 60612, United States

GSK Clinical Trials Call Center, South Bend, Indiana 46617, United States

GSK Clinical Trials Call Center, Indianapolis, Indiana 46202, United States

GSK Clinical Trials Call Center, Louisville, Kentucky 40202, United States

GSK Clinical Trials Call Center, New Orleans, Louisiana 70112, United States

GSK Clinical Trials Call Center, Baltimore, Maryland 21201, United States

GSK Clinical Trials Call Center, Worcester, Massachusetts 01604, United States

GSK Clinical Trials Call Center, Burlington, Massachusetts 01805, United States

GSK Clinical Trials Call Center, Boston, Massachusetts 02111, United States

GSK Clinical Trials Call Center, Ann Arbor, Michigan 48109, United States

GSK Clinical Trials Call Center, St. Loius, Missouri 63110, United States

GSK Clinical Trials Call Center, Omaha, Nebraska 68198, United States

GSK Clinical Trials Call Center, Camden, New Jersey 08103, United States

GSK Clinical Trials Call Center, New Brunswick, New Jersey 08901, United States

GSK Clinical Trials Call Center, Sante Fe, New Mexico 87505, United States

GSK Clinical Trials Call Center, New York, New York 10021, United States

GSK Clinical Trials Call Center, Bronx, New York 10466, United States

GSK Clinical Trials Call Center, New York, New York 10021, United States

GSK Clinical Trials Call Center, Rochester, New York 14642, United States

GSK Clinical Trials Call Center, New Hyde Park, New York 11041, United States

GSK Clinical Trials Call Center, Charlotte, North Carolina 28232, United States

GSK Clinical Trials Call Center, Winston-Salem, North Carolina 27157, United States

GSK Clinical Trials Call Center, Durham, North Carolina 27710, United States

GSK Clinical Trials Call Center, Mayfield Heights, Ohio 44124, United States

GSK Clinical Trials Call Center, Columbus, Ohio 43213, United States

GSK Clinical Trials Call Center, Dayton, Ohio 45409, United States

GSK Clinical Trials Call Center, Portland, Oregon 97213, United States

GSK Clinical Trials Call Center, Hershey, Pennsylvania 17033, United States

GSK Clinical Trials Call Center, Pittsburgh, Pennsylvania 15232, United States

GSK Clinical Trials Call Center, Philadelphia, Pennsylvania 19104, United States

GSK Clinical Trials Call Center, Charleston, South Carolina 29424, United States

GSK Clinical Trials Call Center, Memphis, Tennessee 38104, United States

GSK Clinical Trials Call Center, Knoxville, Tennessee 37920, United States

GSK Clinical Trials Call Center, Memphis, Tennessee 38120, United States

GSK Clinical Trials Call Center, Nashville, Tennessee 37232, United States

GSK Clinical Trials Call Center, Arlington, Texas 76012, United States

GSK Clinical Trials Call Center, Houston, Texas 77030, United States

GSK Clinical Trials Call Center, Houston, Texas 77030, United States

GSK Clinical Trials Call Center, Lubbock, Texas 79410, United States

GSK Clinical Trials Call Center, Salt Lake City, Utah 84112, United States

GSK Clinical Trials Call Center, Yakima, Washington 98902, United States

GSK Clinical Trials Call Center, Spokane, Washington 99202, United States

GSK Clinical Trials Call Center, Seattle, Washington 98109, United States

GSK Clinical Trials Call Center, Milwaukee, Wisconsin 53215, United States

Starting date: January 1998
Last updated: September 7, 2007